How Alendronate (Fosamax) Affects 25-OH Vitamin D Levels

Alendronate Does Not Directly Change 25-OH Vitamin D

Alendronate (brand name Fosamax) is a nitrogen-containing bisphosphonate that binds to hydroxyapatite on bone surfaces and inhibits farnesyl pyrophosphate synthase in osteoclasts, reducing bone resorption [1]. This mechanism operates entirely within the bone remodeling compartment. It does not interfere with vitamin D absorption in the jejunum, hepatic 25-hydroxylation in CYP2R1/CYP27A1 enzymes, or renal 1-alpha-hydroxylation in CYP27B1 [2].

A 2014 systematic review published in the Journal of Clinical Endocrinology & Metabolism examined bisphosphonate trials and found no consistent change in 25-OH vitamin D attributable to alendronate itself when supplementation was controlled [3]. Pre-and-post measurements in these studies showed that 25-OH D levels tracked with supplementation dose, sun exposure, and season rather than with bisphosphonate exposure.

The confusion likely originates from the fact that clinicians routinely co-prescribe vitamin D with alendronate. Patients often see their 25-OH D rise after starting Fosamax, but that increase comes from the supplementation protocol, not the bisphosphonate.

"Alendronate has no known effect on vitamin D metabolism. The observed changes in 25-hydroxyvitamin D after bisphosphonate initiation are attributable to concurrent supplementation, not to the drug itself," per the American Association of Clinical Endocrinologists 2020 guidelines for postmenopausal osteoporosis [4].

Why Vitamin D Status Still Matters on Alendronate

Even though alendronate does not alter 25-OH D levels, the relationship between these two is clinically significant. Vitamin D governs intestinal calcium absorption. Without sufficient 25-OH D (and its active metabolite 1,25-dihydroxyvitamin D), the gut absorbs only 10-15% of dietary calcium instead of the normal 30-40% [2]. That deficit triggers compensatory parathyroid hormone (PTH) secretion.

Elevated PTH drives osteoclastic resorption. This is the opposite of what alendronate is trying to accomplish. A patient taking alendronate while vitamin D-deficient is fighting the drug's mechanism with their own endocrine system.

Data from the Fracture Intervention Trial (FIT) illustrate the point. In FIT, 2,027 postmenopausal women with low femoral neck BMD received alendronate 5-10 mg daily or placebo for a mean of 4.2 years. Alendronate reduced clinical vertebral fractures by 47% (RR 0.53 to 95% CI 0.41-0.68) [5]. All participants received calcium 500 mg and vitamin D 250 IU daily, ensuring a baseline level of vitamin D adequacy.

Post hoc analyses of bisphosphonate trials have consistently shown that patients with 25-OH D <20 ng/mL at baseline gain less bone mineral density (BMD) at the lumbar spine and hip than those with levels above 30 ng/mL [6]. The anti-fracture signal weakens when vitamin D status is poor.

The Indirect Effect: PTH Suppression and Calcium Flux

Alendronate does create one indirect interaction with the vitamin D axis that clinicians should understand. By suppressing osteoclast activity, alendronate reduces the release of calcium from bone into the bloodstream. In a patient with normal vitamin D status, intestinal calcium absorption compensates seamlessly. In a vitamin D-deficient patient, that compensatory pathway is impaired.

The result can be a transient drop in serum calcium. This is especially relevant in the first 1-4 weeks of therapy. A 2006 study in Osteoporosis International reported that 12% of bisphosphonate-treated patients with baseline 25-OH D <15 ng/mL developed transient hypocalcemia (corrected calcium <8.5 mg/dL) within the first month of treatment [7]. None of the patients with baseline 25-OH D above 30 ng/mL experienced this.

The clinical sequence works like this: alendronate reduces calcium efflux from bone. If gut absorption cannot compensate because vitamin D is low, serum calcium drops. PTH rises. The patient enters secondary hyperparathyroidism. Bone resorption markers (CTX, NTX) may not fall as expected. The prescriber might conclude alendronate "isn't working" when the real problem is uncorrected vitamin D deficiency.

Optimal 25-OH Vitamin D Targets Before and During Alendronate

The Endocrine Society's 2011 Clinical Practice Guideline defines vitamin D sufficiency as 25-OH D of 30-50 ng/mL (75-125 nmol/L) for patients on osteoporosis therapy [8]. The National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) aligns with this threshold, specifically recommending a minimum of 30 ng/mL before initiating any antiresorptive agent [9].

For patients presenting with deficiency (25-OH D <20 ng/mL), the standard repletion protocol is ergocalciferol (vitamin D2) 50 to 000 IU once weekly for 8 weeks, followed by maintenance dosing of cholecalciferol (vitamin D3) 1,000-2 to 000 IU daily [8]. Some clinicians prefer cholecalciferol 5,000-7 to 000 IU daily for repletion, which achieves similar results over 8-12 weeks.

Only after the 25-OH D level has been confirmed at 30 ng/mL or above should alendronate be initiated. Starting both simultaneously is common in practice but carries the risk of the hypocalcemia and blunted efficacy described above.

"We check 25-hydroxyvitamin D in every patient before writing a bisphosphonate prescription. If the level is below 30, we replete first and delay the bisphosphonate by 8 to 12 weeks. The fracture risk reduction data only apply when vitamin D is adequate," according to the AACE/ACE 2020 Clinical Practice Guidelines recommendation summary [4].

Monitoring 25-OH Vitamin D During Alendronate Therapy

Because alendronate does not alter 25-OH D levels, monitoring schedules follow general vitamin D surveillance guidelines rather than any drug-specific protocol. A practical monitoring timeline for patients on alendronate includes a baseline 25-OH D before initiating therapy, a recheck at 3 months after repletion (if the patient was deficient), and annual testing thereafter [8].

More frequent testing may be warranted in patients with malabsorption syndromes (celiac disease, inflammatory bowel disease, gastric bypass), those on medications that accelerate vitamin D catabolism (phenytoin, carbamazepine, rifampin), and those with chronic kidney disease stage 3 or higher, where 1-alpha-hydroxylation is impaired [2].

A 2019 cohort study in the Journal of Bone and Mineral Research tracked 4,167 bisphosphonate-treated patients over 3 years and found that 23% fell below 25-OH D of 20 ng/mL at least once during follow-up despite initial supplementation [10]. The most common reasons were seasonal decline in UVB exposure, discontinuation of supplements, and weight gain (vitamin D is fat-soluble and sequestered in adipose tissue). Annual monitoring catches these lapses before they compromise treatment efficacy.

Serum calcium should also be checked at baseline and at 2-4 weeks after starting alendronate, particularly in patients whose 25-OH D was borderline (20-29 ng/mL) at initiation [7].

Supplementation Protocols That Pair with Alendronate

The FIT trial protocol used 500 mg calcium and 250 IU vitamin D daily, doses now considered suboptimal [5]. Current guidelines recommend 1,000-1 to 200 mg of total daily calcium (diet plus supplements) and 1,000-2 to 000 IU of vitamin D3 daily for patients on antiresorptive therapy [9].

There is a timing consideration specific to alendronate. The drug must be taken on an empty stomach with plain water, 30 minutes before any food, beverage, or other medication. Calcium and vitamin D supplements should be taken later in the day, ideally with a meal containing some fat to optimize vitamin D absorption [1].

Calcium carbonate requires gastric acid for absorption and should be taken with food. Calcium citrate does not require acid and can be taken without food, making it a better option for patients on proton pump inhibitors or those who prefer to take supplements between meals [9].

For patients with persistent insufficiency despite standard oral dosing, a 2017 randomized trial in JAMA Internal Medicine demonstrated that cholecalciferol 50 to 000 IU monthly achieved 25-OH D levels above 30 ng/mL in 89% of participants at 12 months, compared to 68% with daily 1 to 000 IU dosing [11].

Populations at Higher Risk for Vitamin D Deficiency on Alendronate

Certain patient groups require heightened vigilance around vitamin D status during alendronate therapy. Post-bariatric surgery patients, particularly those who have undergone Roux-en-Y gastric bypass, have impaired fat-soluble vitamin absorption and may need 3,000-6 to 000 IU of vitamin D3 daily to maintain adequate levels [12].

Older adults (age 70+) produce approximately 75% less cutaneous vitamin D from UVB exposure compared to younger adults, owing to reduced 7-dehydrocholesterol in the skin [2]. Institutionalized or homebound patients have minimal sun exposure. A 2010 analysis in the Archives of Internal Medicine found that 57% of nursing home residents on bisphosphonates had 25-OH D levels below 20 ng/mL, and only 18% were receiving vitamin D doses above 800 IU daily [13].

Patients with darker skin pigmentation, those living at latitudes above 35 degrees north, and individuals with BMI above 30 kg/m² also face higher baseline risk for deficiency and should be tested before starting alendronate [8].

Glucocorticoid-treated patients represent a dual-risk group. Long-term prednisone use (7.5 mg/day or more) accelerates bone loss and simultaneously impairs intestinal calcium absorption through a vitamin D-independent mechanism. The American College of Rheumatology 2022 guidelines recommend bisphosphonate therapy for patients on chronic glucocorticoids with moderate-to-high fracture risk, but only after ensuring 25-OH D is 30 ng/mL or above [14].

What Happens if Vitamin D Drops During Alendronate Treatment

A decline in 25-OH D during ongoing alendronate therapy does not create a dangerous acute event, but it does erode the drug's benefit over time. Bone turnover markers (particularly serum CTX) may rise from their suppressed nadir, signaling increased resorption despite continued bisphosphonate use [6].

BMD gains may plateau or reverse. A 2012 analysis from the FLEX extension trial showed that patients who maintained 25-OH D above 30 ng/mL throughout 10 years of alendronate therapy had 2.4% greater total hip BMD than those whose levels intermittently fell below 20 ng/mL [15].

The clinical response to this situation is straightforward: check 25-OH D, replete if needed, and continue alendronate. There is no need to pause bisphosphonate therapy while correcting vitamin D deficiency unless the patient has symptomatic hypocalcemia (muscle cramps, perioral numbness, QTc prolongation), which is rare in this context [7].

Patients reporting new-onset musculoskeletal pain on alendronate should have 25-OH D checked, as vitamin D deficiency itself can cause diffuse bone and muscle pain that mimics bisphosphonate side effects. Correcting the deficiency often resolves the symptoms without discontinuing the drug [8].